Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Muscle strength |
Measurement of muscle strength by a handheld dynamometer (MicroFet). |
Change from Baseline muscle strength at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Other |
Handgrip strength |
Measurement of handgrip strength using a JAMAR Hand Dynamometer |
Change from Baseline handgrip strength at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Other |
6-minute walk test (6-MWT) |
Testing functional status and fitness, and endurance (walking as far as possible for 6 minutes measuring total distance (meters)). |
Change from Baseline 6-MWT at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Other |
modified Medial Research Council (mMRC) |
Dyspnoea will be evaluated by the modified Medical Research Council.The participants answer the question if they sometimes feel short of breath. If so, they choose the quote that fits them most (score 0 "I feel only short of breath when performing heavy activities" to 4 "I am too short of breath to leave the house or I feel wheezy during dressing and undressing"). |
Change from Baseline mMRC at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Other |
Barthel Index |
The Barthel Index assesses to which extend a person needs help performing activities of daily living (ADL). Classical it consists of 10 items (but other versions exist) each scored for 0 to 1,2,3 on a total of 20. The higher the score the less dependent the individual. |
Change from Baseline Barthel Index at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Other |
Adequacy of feeding |
Adequacy of feeding is the ratio between intake of calories and proteins and the individual need. The amount of proteins, carbohydrates and fatty acids to be eaten by the patient to fulfill the needs, are calculated based on the measured body weight. The caloric target is defined by a metabolic measurement: indirect calorimetry. People can be defined as hypo-, normo- or hypermetabolic when the measured value is compared to a calculated predictive value (e.g. 25 kcal/kg body weight/day). In case that the indirect calorimetry cannot be performed (e.g., claustrophobia), the caloric target will be defined using the best fitting formula (e.g. WHO equations for BMI < 18.5 kg/m², Harris-Benedict equation for normal- and overweight patients). The daily intake is compared to these needs: feeding adequacy. |
Change from Baseline Adequacy of feeding at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Other |
Phase angle |
This parameter is measured by Bio Impedance Analysis (BIA). The phase angle is a measure of cell and thereby body vitality. |
Change from Baseline phase angle at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Other |
Fat-to-fat free mass ratio |
Fat-to-fat free mass ratio us an important characteristic of a human being as it compares fat mass to fat free mass which includes bone muscle mass. |
Change from Baseline fat-to-fat free mass ratio at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Primary |
1-minute sit-to-stand (1-MSTS) |
Testing of endurance and muscle strength of the lower extremities (standing up from a sitting position for as many repetitions as possible during 1 minute) |
Change from Baseline Repetitions Sit-To-Stand's in one minute at 12 weeks |
|
Secondary |
Multi-dimensional Fatigue Inventor (MFI-20) |
The MFI is a self-report instrument designed to measure fatigue and was initially developed in Dutch17 for patients with cancer. It covers the following dimensions: general fatigue, physical fatigue, reduced activity, reduced motivation and mental fatigue. It consists of 20 items divided over 5 dimensions (each 4 items) and is scored on a 5-point Likert scale. The higher the score the more severe the fatigue and by consequence the more impact fatigue has on daily functioning. |
Change from Baseline MFI-20 at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Secondary |
EuroQol five-dimensional (five-level version) (EQ-5D-5L) |
Health-related Quality of Life will be measured by the EQ-5D-5L. This questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels from no problems tot extreme problems. Next it contains a self-rated health status on a vertical visual analogue scale where the endpoints are labelled the best health you can imagine' and 'the worst health you can imagine'. This test has proven valuable for assessing physical health-related QoL (25). |
Change from Baseline EQ-5D-5L at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Secondary |
Post-COVID-19 Functional Status (PCFS) |
Functional status will be evaluated for changes using the PCFS, specifically developed for COVID patients by Klok and colleagues. |
Change from Baseline PCFS at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Secondary |
Hospital Anxiety and Depression Scale (HADS) |
Mental status will be evaluated for differences using HADS.This test is a simple tool to assess both anxiety and depression, each with 7 questions. |
Change from Baseline HADS at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|
Secondary |
Work Productivity and Activity Impairment (WPAI) |
Work capability will also be assessed using the Work Productivity and Activity Impairment. With 6 questions it asks about the decline in productivity and activity in the past 7 days. There are 3 versions available but all evaluate on absence, presence, loss of productivity and decline of activities during work. The WPAI is considered the best validated questionnaire for determining health-related work productivity and has been validated in various chronic inflammatory diseases. |
Change from Baseline WPAI at 12 weeks, at 6 weeks intervention, at 12 weeks, and at 6 weeks post-intervention. |
|